CD274 and malignant colon neoplasm: When mice carrying aggressive lymphomas, breast or colon cancers, which all were insensitive towards ibrutinib treatment, were treated with anti-PDL1 MAb or a combination of anti-PDL1 MAb and ibrutinib, the combination showed significantly enhanced efficacy over anti-PDL1 mAb monotherapy [91].